CDK1 and non-small cell lung carcinoma: For instance, the CDK1 inhibitor, purvalanol A, enhances the taxol-induced apoptosis and inhibitory effects on cellular proliferation of taxol through Op18/stathmin in non-small-cell lung cancer cells in vitro [33].